Syndax Pharmaceuticals will present 19 abstracts at the 68th ASH Annual Meeting (12–15 December 2026). Fourteen cover revumenib (Revuforj), including seven oral presentations, and five cover axatilimab (Niktimvo)…. read more.
A world-first national program has discovered more than a third of babies thought to have a peanut allergy could safely have the diagnosis removed. And the findings are… read more.
Maralixibat can be used as an option to treat cholestatic pruritus in Alagille syndrome in people 2 months and over, only: i) as an add-on to standard first-line… read more.
Rigel Pharmaceuticals will present updated Phase 1b data for R289 at the 68th ASH Annual Meeting, in an oral session on 12 December 2026. R289 is the company’s… read more.
Merck, known as MSD outside of the United States and Canada, announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the… read more.
Lyell Immunopharma will present updated data for rondecabtagene autoleucel (ronde-cel), its investigational dual-targeting CD19/CD20 CAR T-cell therapy, in relapsed or refractory large B-cell lymphoma (LBCL). The data will… read more.
Emergency Medicine & Intensive Care
The label “corridor care” is hiding the true scale of the NHS hospital crisis, warns a senior doctor in The BMJ today. Corridor care refers to the practice… read more.
Endocrinologists who scored highest on the American Board of Internal Medicine’s Longitudinal Knowledge Assessment (LKA®) were more likely to prescribe a key diabetes drug class following a treatment… read more.
The US Food and Drug Administration (FDA) has accepted BeOne Medicines’ supplemental New Drug Application for Brukinsa (zanubrutinib) in combination with rituximab, granting it Priority Review. The application… read more.
NICE has updated its managed access recommendation for exa-cel to include children aged 5 to 11 years, following the MHRA’s extension of the UK marketing authorisation on 29… read more.
Professor Julia Mayerle and colleagues from LMU University Hospital Munich have developed an admission-based score intended to identify pancreatitis patients more likely to be diagnosed with thrombosis during hospitalization…. read more.
Orion Pharma has announced late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2026. The data showed that adding darolutamide, an androgen receptor inhibitor (ARi)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
